Victoria Shaw
University of Liverpool(GB)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Long-Term Effects of COVID-19, Pancreatic and Hepatic Oncology Research, SARS-CoV-2 detection and testing
Most-Cited Works
- → Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial(2014)371 cited
- → Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK(2021)192 cited
- → Neuroprotection of midbrain dopaminergic cells in MPTP‐treated mice after near‐infrared light treatment(2009)142 cited
- → Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study(2021)113 cited
- → Near‐infrared light is neuroprotective in a monkey model of Parkinson disease(2015)108 cited
- → Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study(2021)102 cited
- → Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia(2016)91 cited
- → The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer(2013)91 cited
- → Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease(2014)85 cited
- → Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial(2022)77 cited